SynthesisThe oncologist2025
Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC.
Fabio Salomone et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.